Figma has been upgraded to a buy rating following a strong first quarter where it reported 43% year-over-year revenue growth and raised its revenue outlook to over $1.4 billion for the year. The company continues to show robust customer retention near 140% net expansion, driven by cross-selling and focus on higher-end customers. Trading at about 7 times revenue, Figma is seen as having potential for further valuation gains once market sentiment towards software stocks improves.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...
Auditoria.AI introduced Governed Autonomy, a new framework allowing AI agents to operate within enterprise-defined policies in finance, reducing the need for human approval on every transaction. This shift addresses governance challenges in AI deploy...
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 ...
Microchip Technology has introduced new 3.3 kV HV-D3 mSiC power modules designed to enhance solid-state transformers (SSTs) for AI hyperscale data centers. These modules integrate silicon carbide MOSFETs and Schottky diodes to improve power delivery ...
